logo
logo

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Jun 11, 2020•about 5 years ago

Amount Raised

$63 Million

Round Type

series a

Cambridge

Description

Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 million in a Series A2 financing from both existing and new investors. The Series A2 round was led by existing investor GV (formerly Google Ventures) with participation from current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital. New investors Wellington Management and Casdin Capital also joined the round. This additional financing reflects the company’s strong preclinical progress to date and buildout of a world-class scientific team.

Company Information

Company

Verve Therapeutics

Location

Cambridge, Maryland, United States

About

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing — two of the biggest breakthroughs in 21st century biomedicine — to develop transformative therapies for coronary heart disease. Verve is developing gene-editing therapies, administered once in life, that safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels lifelong, reducing the risk of coronary heart disease and heart attack. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, Biomatics Capital, Wellington Management, Casdin Capital, and Partners Innovation Fund. Verve is headquartered in Cambridge, Massachusetts. For more information, visit www.VerveTx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech